ADMA Q4 2025 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$139M+18.4% YoY

Gross Profit

$89M63.8% margin

Operating Income

$63M45.1% margin

Net Income

$49M35.5% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+3.7%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$35M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$624M

Total Liabilities

$147M

Stockholders' Equity

$477M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$139M	$118M	+18.4%
Gross Profit	$89M	$63M	+40.2%
Operating Income	$63M	$38M	+63.7%
Net Income	$49M	$112M	-55.9%

Geographic Segments

UNITED STATES

$137M99%

Non-US

$2M1%